



PATENT
Customer No. 22,852
Attorney Docket No. 2356.0087

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Yosser BEN ACHOUR et al.) Group Art Unit: 1645
)
Application No.: 10/733,232) Examiner: Jana A. Hines
)
Filed: December 12, 2003)
)
For: GENES ASSOCIATED WITH) Confirmation No.: 4579
LEISHMANIA PARASITE
VIRULENCE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

RESPONSE TO RESTRICTION REQUIREMENT

In a restriction requirement dated June 14, 2005, the Examiner required
restriction under 35 U.S.C. § 121 between the following groups of claims:

- I. Claims 1, 3, 16-19 and 20-22, drawn to a protein and an immunogenic composition and vaccinating composition comprising said protein, classified in class 424, subclass 184.1.
- II. Claims 2-3, 16-19 and 20-22, drawn to a *Leishmania* protein and an immunogenic composition and vaccinating composition comprising said protein, classified in class 424, subclass 269.1.
- III. Claims 1, 4-6, 16-19 and 20-22, drawn to a recombinant polypeptide and an immunogenic composition and vaccinating composition comprising said polypeptide, classified in class 435, subclass 69.1.
- IV. Claims 2, 4-6, 16-19 and 20-22, drawn to a recombinant *Leishmania* protein and an immunogenic composition and vaccinating composition comprising said protein, classified in class 536, subclass 23.1.

- V. Claims 7-12, 16-19 and 20-22, drawn to a recombinant nucleic acid vector, and an immunogenic composition and vaccinating composition comprising said nucleic acid, classified in class 435, subclass 320.1.
- VI. Claim 13, drawn to the use of a nucleic acid probe, classified in class 536, subclass 24.32.
- VII. Claim 14, drawn to a nucleotide primer, classified in class 536, subclass 24.3.
- VIII. Claims 15 and 30-31, drawn to an antibody and pharmaceutical composition, classified in class 424, subclass 130.1.
- IX. Claims 23-25, drawn to a method for screening molecules, classified in class 435, subclass 258.3.
- X. Claims 26-28 and 32-33, drawn to the use of one or more protein disulfide isomerase inhibitors and pharmaceutical compositions, classified in class 536, subclass 24.5.
- XI. Claim 29, drawn to the use of bacitracin, classified in class 530, subclass 320.
- XII. Claims 34-35, drawn to an *in vitro* method for diagnosing an infection and diagnostic kit, classified in class 435, subclass 7.1.


Applicants elect to prosecute claims 2-3, 16-19 and 20-22, drawn to a *Leishmania* protein and an immunogenic composition and vaccinating composition comprising said protein. Applicants reserve the right to file one or more divisional applications claiming the non-elected subject matter.

Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: August 15, 2005
(August 14th being a Sunday)

By: 
Kenneth J. Meyers
Reg. No. 25,146
Phone: (202) 408-4000
Fax: (202) 408-4400